Lisbon calling - wild-type GPCRs and more: Our CEO Jens Frauenfeld is invited speaker at #PEGS, presenting new data on the the direct membrane extraction (DirectMX) of membrane proteins.
We will join the BioEurope (link) from November 11-13 in Hamburg. Our CEO Jens Frauenfeld and André Heuer are looking forward to meet with our current pharma partners as well as new parties involved in membrane protein drug targets and antibody development. See you in Hamburg!
We are looking forward to exciting membrane protein cryoem and of course xray structures at the PSDI2019 in the coming days. Using the Salipro Biotech AB platform you can get more out of membrane proteins then just high resolution - visit our publication list for more details (link)
Our CSO Robin Löving will join the Festival of Biologics Conference in Basel, Switzerland, October 15-17. We present new data on challenging drug targets such as wild-type GPCRs using our unique Salipro direct membrane extraction platform (DirectMX). https://www.terrapinn.com/conference/festival-of-biologics/index.stm
Our CEO, Jens Frauenfeld is an invited speaker at the EMBO workshop “Tools for Structural Biology of Membrane Proteins” 7-9 Oct (Hamburg, Germany). We present new data on challenging drug targets, including the direct membrane extraction (DirectMX) of wild-type GPCRs: https://www.embl-hamburg.de/training/events/2019/TBP19-01/
We are honored to have been receiving the poster award of this years Discovery on Target #BostonDOT19, reflecting the interest to access novel drug targets in unique ways.
We are grateful for the recognition and thank the Cambridge Healthtech Institute for coordinating this great conference and the opportunity to present.
Picture by Will Harney
Out now - our antibody application note!
Find out more how to generate monoclonal antibodies against challenging drug targets like GPCRs and Ion Channels - Salipro® for immunisation, B cell selection and antibody binding characterisation (click here)
We will be at the #NLSdays in Malmö/Sweden (10-12 September) followed by the 17th DiscoveryOnTarget in Boston/USA just a week later (16-19th September)
Salipro Biotech enters into agreement with Top10 Pharma company. Salipro Biotech will apply its expertise and its proprietary membrane protein technology to advance programs on a challenging GPCR selected by the pharmaceutical partner.
Out now: ABC transporters like lipids - so do we! The second publication on an active ABC transporter in Salipro® in a month - this time from the Tidow lab in Hamburg, Germany - link to publication : https://www.degruyter.com/view/j/bchm.ahead-of-print/hsz-2019-0171/hsz-2019-0171.xml
Membrane protein research suffers from the drawback that detergents, which are commonly used to solubilize integral membrane proteins (IMPs), often lead to protein instability and reduced activity. Recently, lipid nanodiscs (NDs) and saposin-lipoprotein particles (Salipro) have emerged as alternative carrier systems that keep membrane proteins in a native-like lipidic solution environment and are suitable for biophysical and structural studies. Here, we systematically compare nanodiscs and Salipros with respect to long-term stability as well as activity and stability of the incorporated membrane protein using the ABC transporter MsbA as model system.